Why Merus N.V. (MRUS) Crashed On Wednesday
We recently published a list of Investors Are Dumping These 10 Stocks.
Merus N.v. (MRUS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Commodore Capital Egen Atkinson And Michael Kramarz | 4,472,840 | $188,261,836 | +16% | 13.87% |
| 2. | Deerfield Management James E. Flynn | 3,173,928 | $133,590,630 | +7% | 2.64% |
| 3. | VenBio Select Advisor Kurt Von Emster | 3,000,000 | $126,270,000 | +42% | 1.97% |
| 4. | Samlyn Capital Robert Pohly | 2,379,428 | $100,150,125 | -11% | 1.48% |
| 5. | Holocene Advisors Brandon Haley | 1,873,625 | $78,860,876 | -1% | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.38 | 14,706 | $211,431.10 | 40,576 | 2022-11-03 | Filing | |
| $22.92 | 5,826 | $133,558.14 | 25,870 | 2022-08-22 | Filing | |
| $22.99 | 704 | $16,186.93 | 20,044 | 2022-08-19 | Filing | |
| $22.97 | 4,340 | $99,684.59 | 19,340 | 2022-07-12 | Filing | |
| $19.75 | 26,894 | $531,156.50 | 462,015 | 2021-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $52.76 | 34,000 | $1,793,840.00 | 0 | 2025-06-20 | Filing | |
| $48.55 | 1,000 | $48,550.00 | 11,002 | 2025-03-21 | Filing | |
| $48.48 | 3,000 | $145,440.00 | 12,002 | 2025-03-21 | Filing | |
| $54.00 | 2,500 | $135,000.00 | 7,002 | 2024-08-21 | Filing | |
| $54.00 | 2,500 | $135,000.00 | 7,002 | 2024-08-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,966,914 | $293,237,411 | 0.02% | |
| 2. | 4,718,172 | $198,587,859 | 0.04% | |
| 3. | 4,169,393 | $175,489,751 | 2.68% | |
| 4. | 3,369,699 | $141,830,631 | 6.5% | |
| 5. | 1,991,193 | $83,809,316 | 0.02% |
News See All
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT
The decision follows Merus' highly favorable Phase 2 trial results for the combination of petosemtamab and pembrolizumab in treating first-line head and neck squamous cell carcinoma/HNSCC.
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data
The revision comes after encouraging Phase 2 data for Merus' drug candidates petosemtamab and pembrolizumab (pembro) were released.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
10 Best High Short Interest Stocks to Buy Now
Aditya Bhave, BofA Securities head of US Economics, joined 'Power Lunch' on CNBC on April 17 to talk about whether tariffs are ultimately inflationary, disinflationary, or deflationary.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
10 Jim Cramer Stocks to Watch in 2025
Jim Cramer in a latest program on CNBC commented on the bearish start of 2025 and said being a bear in the market is “easy” because when the stocks rise no one would remember your outlook but if they...
Jim Cramer's Lightning Rounds: 12 Stocks Under the Spotlight
Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following a year of strong gains, cautioning that investors’ overly optimistic expectations for Federal Reserve rate...
10 Most Promising Cancer Stocks According to Hedge Funds
According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide.
10 Top Performing European Stocks Heading into 2025
As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index increased 2% in October as compared to the year earlier.